NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Dow Inc. ("Dow" or the "Company") (NYSE:DOW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Dow and certain of its officers and/or directors […]
NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc.("Replimune" or the "Company") (NASDAQ:REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Fiserv, Inc. ("Fiserv" or the "Company") (NYSE:FI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against XPLR Infrastructure, LP ("XPLR" or the "Company") (NYSE:XIFR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Reckitt Benckiser Group Plc ("Reckitt" or the "Company") (OTCQX:RBGLY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are
NEW YORK, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ:MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Mereo and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NeoGenomics and certain of its officers and/or directors
NEW YORK, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Groupon, Inc. ("Groupon" or the "Company") (NASDAQ:GRPN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Groupon and certain of its officers and/or directors have
NEW YORK, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of KBR, Inc. ("KBR" or the "Company") (NYSE:KBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether KBR and certain of its officers and/or directors have
NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Unicycive and certain of its officers and/or